放射诱导的乳腺血管肉瘤:回顾性病例系列的结果。

Clinical Sarcoma Research Pub Date : 2017-08-07 eCollection Date: 2017-01-01 DOI:10.1186/s13569-017-0081-7
R B Cohen-Hallaleh, H G Smith, R C Smith, G F Stamp, O Al-Muderis, K Thway, A Miah, K Khabra, I Judson, R Jones, C Benson, A J Hayes
{"title":"放射诱导的乳腺血管肉瘤:回顾性病例系列的结果。","authors":"R B Cohen-Hallaleh,&nbsp;H G Smith,&nbsp;R C Smith,&nbsp;G F Stamp,&nbsp;O Al-Muderis,&nbsp;K Thway,&nbsp;A Miah,&nbsp;K Khabra,&nbsp;I Judson,&nbsp;R Jones,&nbsp;C Benson,&nbsp;A J Hayes","doi":"10.1186/s13569-017-0081-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or small retrospective series. We sought to describe the management and outcomes of RIAS in a large single-institution series.</p><p><strong>Methods: </strong>All patients diagnosed with RIAS between January 2000 and January 2014 were identified from an institutional database.</p><p><strong>Results: </strong>A total of 49 patients were identified. Median age at diagnosis was 72 years (range 51-93). Median time from completion of radiotherapy to diagnosis of RIAS was 7.5 years. Median tumour size at presentation was 5.0 cm (1.5-19.0). The majority of patients presented with localised disease (47, 95.9%). Of these, 35 (74.5%) were suitable for surgery and underwent surgery with curative intent. Twelve patients presented with localised irresectable disease. Of these, 7 received systemic chemotherapy, with a sufficient response to facilitate surgery in 3 patients. Following potentially curative surgery, 2-year local recurrence-free was 55.2%. Survival was significantly prolonged in patients presenting with resectable disease (2-year overall survival 71.1% vs 33.3%, p < 0.001). Tumour size >5 cm was prognostic of distant metastases-free survival and overall survival.</p><p><strong>Conclusion: </strong>RIAS are rare, aggressive soft-tissue lesions with limited treatment options and high-rates of both local and systemic relapse.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"7 ","pages":"15"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-017-0081-7","citationCount":"41","resultStr":"{\"title\":\"Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series.\",\"authors\":\"R B Cohen-Hallaleh,&nbsp;H G Smith,&nbsp;R C Smith,&nbsp;G F Stamp,&nbsp;O Al-Muderis,&nbsp;K Thway,&nbsp;A Miah,&nbsp;K Khabra,&nbsp;I Judson,&nbsp;R Jones,&nbsp;C Benson,&nbsp;A J Hayes\",\"doi\":\"10.1186/s13569-017-0081-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or small retrospective series. We sought to describe the management and outcomes of RIAS in a large single-institution series.</p><p><strong>Methods: </strong>All patients diagnosed with RIAS between January 2000 and January 2014 were identified from an institutional database.</p><p><strong>Results: </strong>A total of 49 patients were identified. Median age at diagnosis was 72 years (range 51-93). Median time from completion of radiotherapy to diagnosis of RIAS was 7.5 years. Median tumour size at presentation was 5.0 cm (1.5-19.0). The majority of patients presented with localised disease (47, 95.9%). Of these, 35 (74.5%) were suitable for surgery and underwent surgery with curative intent. Twelve patients presented with localised irresectable disease. Of these, 7 received systemic chemotherapy, with a sufficient response to facilitate surgery in 3 patients. Following potentially curative surgery, 2-year local recurrence-free was 55.2%. Survival was significantly prolonged in patients presenting with resectable disease (2-year overall survival 71.1% vs 33.3%, p < 0.001). Tumour size >5 cm was prognostic of distant metastases-free survival and overall survival.</p><p><strong>Conclusion: </strong>RIAS are rare, aggressive soft-tissue lesions with limited treatment options and high-rates of both local and systemic relapse.</p>\",\"PeriodicalId\":10684,\"journal\":{\"name\":\"Clinical Sarcoma Research\",\"volume\":\"7 \",\"pages\":\"15\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s13569-017-0081-7\",\"citationCount\":\"41\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Sarcoma Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13569-017-0081-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-017-0081-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

摘要

背景:乳房放射诱导血管肉瘤(RIAS)是一种罕见且侵袭性的放射治疗并发症。由于这种疾病的罕见性,其管理的大部分证据是基于病例报告或小型回顾性系列。我们试图在一个大型的单一机构系列中描述RIAS的管理和结果。方法:所有2000年1月至2014年1月诊断为RIAS的患者均从机构数据库中确定。结果:共发现49例患者。诊断时的中位年龄为72岁(范围51-93岁)。从放疗完成到诊断为RIAS的中位时间为7.5年。肿瘤出现时的中位大小为5.0 cm(1.5-19.0)。大多数患者表现为局部病变(47例,95.9%)。其中,35例(74.5%)适合手术,并以治疗为目的进行手术。12例患者表现为局部不可切除的疾病。其中7例患者接受了全身化疗,其中3例患者有足够的反应以促进手术。术后2年局部无复发率为55.2%。可切除疾病患者的生存期显著延长(2年总生存率71.1% vs 33.3%, p 5 cm是远处无转移生存和总生存的预后。结论:RIAS是一种罕见的侵袭性软组织病变,治疗方案有限,局部和全身复发率高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series.

Background: Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or small retrospective series. We sought to describe the management and outcomes of RIAS in a large single-institution series.

Methods: All patients diagnosed with RIAS between January 2000 and January 2014 were identified from an institutional database.

Results: A total of 49 patients were identified. Median age at diagnosis was 72 years (range 51-93). Median time from completion of radiotherapy to diagnosis of RIAS was 7.5 years. Median tumour size at presentation was 5.0 cm (1.5-19.0). The majority of patients presented with localised disease (47, 95.9%). Of these, 35 (74.5%) were suitable for surgery and underwent surgery with curative intent. Twelve patients presented with localised irresectable disease. Of these, 7 received systemic chemotherapy, with a sufficient response to facilitate surgery in 3 patients. Following potentially curative surgery, 2-year local recurrence-free was 55.2%. Survival was significantly prolonged in patients presenting with resectable disease (2-year overall survival 71.1% vs 33.3%, p < 0.001). Tumour size >5 cm was prognostic of distant metastases-free survival and overall survival.

Conclusion: RIAS are rare, aggressive soft-tissue lesions with limited treatment options and high-rates of both local and systemic relapse.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍: Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
期刊最新文献
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response. The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma. Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report. Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1